Today: 20 March 2026
Subscribe
Browse Category

Biotechnology 13 December 2025 - 20 December 2025

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, offering $14.50 per share. Amicus stock jumped roughly 30% to $14.18 on heavy volume, trading just below the bid as investors assess deal closure risks. Both boards approved the transaction, with closing targeted for Q2 2026 pending shareholder and regulatory approvals.
20 December 2025
·····
Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific shares rose 1.27% to $569.54 Friday after the company announced enrollment of the first patient in its PPD CorEvitas Alzheimer’s Disease Registry. The initiative aims to collect global real-world data on Alzheimer’s therapies. Thermo Fisher also opened a new collaboration center for life sciences startups in Philadelphia. Market cap stood near $218 billion.
19 December 2025
··
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics shares jumped 8.79% to close at $23.01 on Dec. 19 after a volatile session and recent losses. The move coincided with elevated trading volume and options expiration. The company is advancing therapies for muscular dystrophies and cardiac conditions, with key clinical updates expected in late 2025 and beyond.
19 December 2025
···
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical will acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, paying $14.50 per share—a 33% premium to Amicus’ prior close. The transaction, approved by both boards, is expected to close in Q2 2026 pending shareholder and regulatory approvals. BioMarin will fund the deal with cash and $3.7 billion in debt financing. The acquisition adds two rare-disease drugs and a Phase 3 pipeline asset.
19 December 2025
····
Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)

Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)

Thermo Fisher Scientific said Thursday it enrolled the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry, aimed at collecting real-world evidence on neurodegenerative care. Shares traded near $561 in the afternoon, down slightly after a 1.33% drop Wednesday. The registry will track long-term safety and effectiveness of Alzheimer’s treatments, including MRI-based monitoring of drug side effects.
18 December 2025
··
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics shares fell 8.8% to $20.35 on Thursday, with no new company news released that day. The stock traded between $20.33 and $22.81 on volume of about 1.25 million shares. EWTX remains 38% below its 52-week high and 92% above its 52-week low. The company’s recent updates include a December stock option grant and a November board appointment.
18 December 2025
··
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed shares fell 16% Thursday after the company said its Phase 2b trial of brensocatib in chronic rhinosinusitis without nasal polyps failed to meet endpoints, prompting it to end development for that indication. The drug’s performance matched or trailed placebo on symptom scores. Insmed reported no new safety issues. The stock traded near $166.75 after hitting a low of $158.06.
18 December 2025
···
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals shares fell 6.61% to A$11.73 on the ASX December 17, with volume at 6.36 million and a 52-week low of A$11.535. Nasdaq-listed shares dropped 6–7% in early U.S. trading. The company issued a statement confirming completion of Part 1 enrollment in its ProstACT Global Phase 3 study after market rumors. TLX591 has not received marketing authorization.
17 December 2025
···
Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience shares rose about 6% to $33 by late morning Dec. 17 after new partnership news, recent product launches, and a Barclays price target hike to $39. The company signed a licensing deal with Aptamer Group for use in PCR and NGS products and launched new plasmid DNA preps. Investors are watching progress toward breakeven targeted for fiscal Q4 2026.
17 December 2025
··
Aditxt (ADTX) Stock Surges After Proxy Filing Sets Up Reverse Split Vote and “bitXbio” Name Change — What to Know on Dec. 17, 2025

Aditxt (ADTX) Stock Surges After Proxy Filing Sets Up Reverse Split Vote and “bitXbio” Name Change — What to Know on Dec. 17, 2025

Aditxt shares surged late December 17 after the company filed a definitive proxy for a January 30, 2026, special shareholder meeting. The agenda includes votes on potential share dilution, a reverse stock split, and a rebrand to “bitXbio, Inc.” Traders responded to the capital structure moves, not clinical news.
17 December 2025
··
Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics shares fell about 6% to $60.73 Tuesday, swinging between $58.95 and $65.69 intraday after recent gains. The drop followed positive Phase 2b results for its oral obesity drug aleniglipron and a $747.5 million equity raise. Trading volume was below average, with some reports noting declines up to 9% during the session.
16 December 2025
···
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics shares fell 9% to $79.44 on December 16, 2025, after UBS initiated coverage at Neutral with a $95 target, citing valuation concerns. The stock had surged about 75% year-to-date. No major clinical or regulatory news drove the drop. Trading volume reached approximately 1.27 million shares.
16 December 2025
···
Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

Wave Life Sciences shares rose 5.2% to $16.94 Tuesday after Oppenheimer raised its price target to $32, citing positive interim Phase 1 data for obesity drug WVE-007. The company reported a 9.4% reduction in visceral fat and a 3.2% increase in lean mass at three months after a single dose. Placebo participants saw no significant changes. Wave’s trial enrolled over 100 adults with BMI 28–35.
16 December 2025
··
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure shares jumped about 15% to $23.50 in pre-market trading Dec. 16 after a 10% after-hours gain, despite ongoing FDA uncertainty over its Huntington’s disease gene therapy, AMT-130. The FDA told uniQure its Phase I/II data are “currently unlikely” to support a Biologics License Application, prompting the company to seek further talks in early 2026.
16 December 2025
··
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome reported positive Phase 3 results for varegacestat in desmoid tumors, showing an 84% reduction in risk of progression or death versus placebo. The company also announced a proposed $400 million stock offering, raising concerns about dilution. Most side effects were mild, but 55.6% of premenopausal women experienced ovarian toxicity. Shares moved sharply on the news.
16 December 2025
··
Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant closed a $550 million stock offering on December 12, 2025, selling 26.2 million shares at $21 each. Roivant Sciences bought 16.7 million shares, investing about $350 million and increasing its stake. IMVT shares ended the week at $26.42, up 6.6% after heavy trading. The company plans to use proceeds to fund clinical trials and general operations.
14 December 2025
·
Amicus Therapeutics (FOLD) Stock News, Forecasts and Analyst Outlook on Dec. 14, 2025: What’s Driving the Rally?

Amicus Therapeutics (FOLD) Stock News, Forecasts and Analyst Outlook on Dec. 14, 2025: What’s Driving the Rally?

Amicus Therapeutics shares closed at $10.55 Friday, up 6.6% after hitting a 52-week high of $10.85. Renewed bullish analyst coverage, including a Zacks “strong buy” and a mean price target of $15.90, followed the move. The company’s profitability trajectory and recent earnings have drawn increased attention from investors.
14 December 2025
··
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL shares closed Friday at A$183.93, up 2.86% on the day but down 0.85% for the week. The company reported five-year data for its hemophilia B gene therapy HEMGENIX, showing 94% of patients remained free from continuous treatment. Investors also weighed scrutiny of CSL Seqirus vaccine deals and the ongoing A$750 million buyback.
14 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals shares closed at $452.04 Friday, up 2.26% for the week after rebounding from early losses. The move followed new pediatric data for CASGEVY, showing children ages 5–11 with sickle cell disease remained crisis-free for at least 12 months. Vertex plans global regulatory submissions in 2026. One beta thalassemia patient died from pre-transplant chemotherapy complications.
13 December 2025
··
1 … 6 7 8 9 10 … 16

Stock Market Today

  • Silicon Motion (SIMO) Rises Despite Market Downturn, Strong Earnings Anticipated
    March 19, 2026, 7:45 PM EDT. Silicon Motion (SIMO) closed up 1.67% at $127.50, outperforming the S&P 500's 0.28% decline. Despite a 5.54% drop over the past month, SIMO is set for a significant earnings report, with analysts predicting $1.23 per share - a 105% year-over-year surge. Revenue is expected to reach $299.61 million, up nearly 80% from last year. Full-year projections show earnings of $5.8 per share and revenues hitting $1.27 billion, marking growth of 63% and 43% respectively. The stock holds a Zacks Rank #1 (Strong Buy), with recent upward estimate revisions signaling confidence. SIMO trades at a forward price-to-earnings (P/E) ratio of 21.61, slightly above its industry average, and maintains a PEG ratio of 0.77, matching its sector. The Computer - Integrated Systems industry ranks in the top 10%, underpinning favorable future performance prospects.
Go toTop